206A.T
PRISM BioLab Co.,LTD
グロース · 医薬品 · 医薬品 · JP
JPY 173.00
+1.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +122.0%
- EBITDA
- —
- EBIT
- +1.0%
- Net income
- +20.6%
- EPS
- +31.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026